Tilray (TLRY) has been among the most volatile stocks compared to other cannabis players (MJ) including Canopy Growth (WEED), Aurora Cannabis (ACBFF), and Aphria (APHQF). The company has returned nearly 241% since its debut in July. Tilray has garnered a lot of attention since its IPO. Earlier this week, the company announced a partnership with Novartis to make co-branded products for international markets.
Analysts’ consensus recommendation on Tilray in December is a “hold” recommendation—unlike what we saw for Canopy Growth, Aurora Cannabis, and Aphria. Among the five analysts in the above chart, two recommend a “buy,” while three recommend a “hold.” None of the analysts recommend a “sell” on the stock.
The current consensus target price on Tilray stock is $140, which didn’t change month-over-month. Tilray stock closed at $76.5 on December 18. Based on the current levels, analysts’ target price on Tilray indicates an upside of nearly 83%.
Analysts can be more optimistic than the market, but the divergence in the target and market price shows how differently investors and analysts view the stock.